Anebulo Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
OTC.Pink
Nantahala Capital Management and its managing members disclosed an 8.53% beneficial ownership stake in Anebulo Pharmaceuticals, including exercisable warrants.
OTC.Pink
Mangrove Partners IM, LLC and Nathaniel August have reported a passive beneficial ownership of 6.15% of Anebulo Pharmaceuticals, Inc.'s common stock as of December 31, 2024.
OTC.Pink
Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 8.63% in Anebulo Pharmaceuticals, Inc. as of December 31, 2024.